We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Serum Beta‐Synuclein Is Higher in Down Syndrome and Precedes Rise of pTau181.
- Authors
Oeckl, Patrick; Wagemann, Olivia; Halbgebauer, Steffen; Anderl‐Straub, Sarah; Nuebling, Georg; Prix, Catharina; Loosli, Sandra V.; Wlasich, Elisabeth; Danek, Adrian; Steinacker, Petra; Ludolph, Albert C.; Levin, Johannes; Otto, Markus
- Abstract
This exploratory case–control study investigates the synaptic marker beta‐synuclein in serum and plasma pTau181 in adults with Down syndrome (DS) with (sDS, n = 14) and without (aDS, n = 47) clinical symptoms of Alzheimer disease (AD) as well as euploid controls (n = 23). Beta‐synuclein was higher in aDS and more pronounced in sDS (p < 0.0001), whereas pTau181 was only higher in sDS (p < 0.0001). Both markers showed good discriminatory power (area under the curve > 0.90) to distinguish symptomatic from asymptomatic AD. The data indicate that synaptic alterations belong to the earliest AD‐associated events in DS and highlight the value of serum beta‐synuclein as a potential early marker of AD. ANN NEUROL 2022;92:6–10
- Subjects
DOWN syndrome; ALZHEIMER'S disease; SYMPTOMS; BIOMARKERS
- Publication
Annals of Neurology, 2022, Vol 92, Issue 1, p6
- ISSN
0364-5134
- Publication type
Article
- DOI
10.1002/ana.26360